HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jung, R. C. Articles by Katz, F. F. Search for Related Content PubMed PubMed Citation Articles by Jung, R. C. Articles by Katz, F. F.

Fumagillin and Erythromycin in the Treatment of Amebiasis¹

In preliminary trials of fumagillin and erythromycin in Louisiana and Mississippi, 45 patients were treated. Of fifteen patients with E. histolytica infection receiving fumagillin, four suffered recurrences. Eight persons with amebiasis treated with erythromycin 600 mg. every six hours were cured. Of sixteen individuals treated with 30 mg. per kilogram of body weight per day four suffered recurrences. Both drugs caused the temporary disappearance of nonpathogenic amebae from the stools.

One-hundred twenty Panamanian patients were treated for amebiasis with fumagillin, erythromycin or a combination of both drugs. There was failure or recurrence of infection within seven weeks in over 15 per cent of 39 treated with fumagillin, no failure or recurrence in 18 treated with erythromycin and only one recurrence out of 63 patients treated concurrently with both drugs. These differences were not statistically significant.

A definite effect upon nonpathogenic amebae was observed with each type of treatment but there was a high rate of recurrence. In the case of each species of amebae, Endolimax nana, Entamoeba coli, and Iodamoeba bütschlii there was a higher rate of recurrence with fumagillin treatment than with erythromycin or concurrent use of both drugs. These differences were not statistically significant.

Erythromycin provided rapid relief of amebic dysentery in three of four patients, fumagillin in one of two and combined therapy in three of three.

¹ This study was carried out with the assistance of funds and drugs granted by Abbott Laboratories.

This article has been cited by other articles:

				H.M. Gilles and A.B. Tompkins Treatment of Intestinal Parasites in Children Clinical Pediatrics, October 1, 1962; 1(1): 32 - 38. [PDF]

				R. C. JUNG and E. C. FAUST THE TREATMENT OF INTESTINAL PARASITIC INFECTIONS Arch Intern Med, October 1, 1956; 98(4): 495 - 504. [Abstract] [PDF]